Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ ...

Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune ...

One of the world’s leading investment firms has broken its own record with the closing of its $6.3 billion Blackstone Life ...

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

After being knocked back in 2024, serial biotech acquirer Kevin Tang has used a different route to finally get his hands on Kezar Life Sciences.   | Autoimmune specialist Aurinia, which named Kevin ...

Merck & Co. has lifted the lid on the third successful phase 3 trial of its PCSK9 inhibitor, showing the edge the cardiovascular disease prospect has over other oral non-statin therapies.

Not content with lining up one potential rival to Amgen’s Tepezza, Viridian Therapeutics has scored a phase 3 win for another thyroid eye disease (TED) prospect. But the candidate's inability to meet ...

Kardigan’s tonlamarsen reduced a key biomarker for hypertension in a phase 2 trial, but missed the study’s other goal of significantly reducing blood pressure. The biotech evaluated monthly 90 mg ...

Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is ...

Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...

Kailera Therapeutics—one of the biggest money-raisers of 2025—is now planning to go public as it seeks further funding to push its obesity portfolio through the clinic. | Kailera Therapeutics—one of ...